Ribo Licenses siRNA Platform to Madrigal in $4.4B MASH Deal
Event summary
- Ribo and Ribocure granted Madrigal exclusive global license for six pre-clinical siRNA programs targeting MASH.
- $60M upfront payment with potential $4.4B in milestone payments and royalties.
- Collaboration leverages Ribo's GalSTARTM platform for liver-targeted siRNA therapies.
- Option to expand to bi-specific siRNAs targeting multiple disease-causing genes.
The big picture
This deal positions Ribo as a key player in the rapidly evolving MASH treatment landscape, following Madrigal's successful launch of the first approved MASH therapy. The collaboration underscores the growing importance of siRNA technologies in addressing metabolic liver diseases, with potential to reshape the therapeutic landscape through multi-mechanistic approaches.
What we're watching
- Therapeutic Efficacy
- Whether Ribo's siRNA platform can deliver differentiated outcomes in MASH treatment compared to existing therapies.
- Development Timeline
- The pace at which the pre-clinical assets advance through clinical trials and regulatory approvals.
- Commercial Potential
- How Madrigal's commercialization expertise will impact global market penetration of these novel MASH therapies.
Related topics